Oncology – Gastrointestinal
RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia
10 Jan, 2023 | 14:09h | UTC
ASCO Guideline | Immunotherapy and targeted therapy for advanced gastroesophageal cancer
9 Jan, 2023 | 14:40h | UTC
Phase 1-2 study | Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
9 Jan, 2023 | 14:04h | UTCAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Advanced Colorectal Cancer Treatment Targets KRAS Gene With Drug Combo – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody. https://t.co/nCoEPeV9oB pic.twitter.com/FCHxU9WCin
— NEJM (@NEJM) December 21, 2022
M-A | Laparoscopic vs. open pancreatoduodenectomy in patients with periampullary tumors
9 Jan, 2023 | 14:02h | UTCLaparoscopic versus Open Pancreatoduodenectomy in Patients with Periampullary Tumors: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Review | Role of AI and digital pathology for colorectal immuno-oncology.
16 Dec, 2022 | 13:11h | UTCRole of AI and digital pathology for colorectal immuno-oncology – British Journal of Cancer
A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.
16 Dec, 2022 | 13:09h | UTC
RCT | Assessment of spleen-preserving hilar lymphadenectomy for advanced proximal gastric cancer without invasion into the greater curvature.
15 Dec, 2022 | 13:30h | UTCAssessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract and Video Summary
Phase 2 RCT | Immediate surgery vs. short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer.
14 Dec, 2022 | 15:01h | UTCNews Release: Chemotherapy before surgery can improve survival rates in pancreatic cancer patients – University of Liverpool
Commentary on Twitter
New research – Ghaneh et al – Immediate surgery vs short-course neoadjuvant gemcitabine + capecitabine, FOLFIRINOX, or chemoradiotherapy in patients w/ borderline resectable #pancreaticcancer (ESPAC5): a randomised phase 2 trialhttps://t.co/9S1hupyKjg#gitwitter #onctwitter pic.twitter.com/g2jQUAhUSJ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 14, 2022
Review | Interventional gastroenterology in oncology.
12 Dec, 2022 | 12:46h | UTCInterventional gastroenterology in oncology – CA: A Cancer Journal for Clinicians
Post-trial follow-up | Bursectomy vs. omentectomy alone for resectable gastric cancer.
12 Dec, 2022 | 12:26h | UTCFive-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001) – British Journal of Surgery (link to abstract – $ for full-text)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
15 Nov, 2022 | 12:52h | UTC
Commentary from the author on Twitter
https://twitter.com/ArndtVogel/status/1590634413377081344
Phase 2 RCT | Efficacy of Bemarituzumab in patients with FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma.
11 Nov, 2022 | 13:02h | UTCBemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
🔥Targeting FGFR2b in gastric & gastro-oesophageal junction adenocarcinoma🔥@TheLancetOncolhttps://t.co/Rc6AGRIf4a
✅FIGHT: FOLFOX6 + plc. vs bemarituzumab
👉mPFS: 9.5 vs 7.5 mo, n.s.
👉mOS: 19.2 vs 13.5 mo
⛔️eye tox & stomatitis
✅FORTITUDE-101/102 ongoing@myESMO @OncoAlert pic.twitter.com/JTL23o23dY— Arndt Vogel (@ArndtVogel) October 17, 2022
NICE Guideline Update | Colonoscopic surveillance in adults with inflammatory bowel disease or adenomas.
10 Nov, 2022 | 14:16h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
M-A | Efficacy of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer.
4 Nov, 2022 | 13:22h | UTC
Cohort Study | Mental health morbidities and time to cancer diagnosis among adults with colon cancer in England.
3 Nov, 2022 | 13:55h | UTCInvited Commentary: The Interface Between Colon Cancer and Mental Health Morbidities – JAMA Network Open
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
31 Oct, 2022 | 13:51h | UTCRelated Guideline: ASCO Guideline | Treatment of metastatic colorectal cancer.
Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.
31 Oct, 2022 | 13:47h | UTC
Cohort Study | Diverticular disease linked to increased risk of cancer outside the GI tract.
31 Oct, 2022 | 13:33h | UTCCancer risk in patients with diverticular disease: a nationwide cohort study – JNCI: Journal of the National Cancer Institute (link to abstract – $ for full-text)
News Release: Diverticular disease associated with cancer outside gastrointestinal tract – Karolinska Institutet
Expert Consensus | Imaging standardization in metastatic colorectal cancer.
26 Oct, 2022 | 14:36h | UTC
Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.
24 Oct, 2022 | 14:01h | UTCRandomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network
Commentary on Twitter
Phase II CheckPAC Trial in refractory #PancreaticCancer
✅ 37.2% of pts achieved clinical benefit after stereotactic #RadiationTherapy in combination w/ nivolumab and ipilimumab
⛔ PD-L1 score was not associated with benefitRead more: https://t.co/rxDnYvIUMl #JCO #PancSM pic.twitter.com/u7FfQEwN7a
— Journal of Clinical Oncology (@JCO_ASCO) May 9, 2022
ASCO Guideline | Treatment of metastatic colorectal cancer.
20 Oct, 2022 | 12:32h | UTCTreatment of Metastatic Colorectal Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary: ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic CRC – ASCO Daily News
Commentary on Twitter
‼️ @ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer
Read in #JCO ➡️ https://t.co/CqWdEoSIjd #crcsm #mCRC pic.twitter.com/3N25Fl02v6
— Journal of Clinical Oncology (@JCO_ASCO) October 17, 2022
Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.
20 Oct, 2022 | 12:24h | UTCNews Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh
Commentary from the author on Twitter (thread – click for more)
A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath pic.twitter.com/hMJQ4OAUld
— Aatur Singhi, MD PhD (@PancPathologist) October 10, 2022
NCCN Guideline | Rectal cancer.
19 Oct, 2022 | 14:25h | UTC
Cohort Study | Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer.
17 Oct, 2022 | 12:14h | UTC
15-year benefits of sigmoidoscopy screening on colorectal cancer incidence and mortality: a pooled analysis of randomized trials.
13 Oct, 2022 | 13:48h | UTC15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians
Related:
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Commentary on Twitter
A pooled analysis evaluating 15-yr effect of sigmoidoscopies found that receiving 1 #sigmoidoscopy significantly reduces long-term incidence of CRC in men and women: https://t.co/QXj5VRMHeo pic.twitter.com/s82sOJmBzr
— Annals of Int Med (@AnnalsofIM) October 11, 2022